{"id":"cmab015","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of CMAB015 has not been widely disclosed in public literature, it is developed as an immunotherapeutic monoclonal antibody by Taizhou Mabtech Pharmaceutical. As a Phase 3 candidate, it is likely designed to modulate immune responses against cancer cells, potentially through checkpoint inhibition or direct tumor antigen targeting.","oneSentence":"CMAB015 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:28.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07254325","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2025-12-15","conditions":"Psoriasis","enrollment":114},{"nctId":"NCT06398652","phase":"PHASE3","title":"Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-08-27","conditions":"Psoriasis","enrollment":336},{"nctId":"NCT05734482","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-02-15","conditions":"Psoriasis","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CMAB015","genericName":"CMAB015","companyName":"Taizhou Mabtech Pharmaceutical Co.,Ltd","companyId":"taizhou-mabtech-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}